Bendamustine versus Fludarabine/Cyclophosphamide for White Blood Cell Reduction in the Context of CAR-T Cell Therapy: A Randomized Trial
There are various options for treating large B-cell lymphoma. One of them is CAR-T cell therapy. In this procedure, specific immune cells (T cells) are filtered out of the patient’s blood. In the laboratory, the T cells are multiplied and modified so that they can attack cancer cells. The modified T cells (CAR-T cells) are then administered to the patient via infusion, and once inside the patient’s body
destroy the cancer cells.
Before the CAR-T cells can be administered, it is necessary to undergo a course of treatment lasting two to three days. This destroys many white blood cells in the body and increases the likelihood that the CAR-T cells will be able to fight the lymphoma cells over a longer period of time. The active ingredients fludarabine and cyclophosphamide are typically used for this therapy.
This study investigates whether the treatment can also be administered using the active ingredient bendamustine. It is hoped that bendamustine will cause fewer side effects than fludarabine and cyclophosphamide. Bendamustine is already approved in Switzerland for the treatment of cancer.
Intervention Studied
In the study, participants are randomly assigned to two groups:
- Participants in Group 1 receive bendamustine therapy prior to the CAR-T cell infusion. Bendamustine is administered as an infusion on days 4 and 3 before the CAR-T cell infusion. The bendamustine infusion lasts 30–60 minutes.
- Participants in Group 2 will receive treatment with fludarabine and cyclophosphamide prior to the CAR-T cell infusion. Both drugs will be administered as infusions on days 5, 4, and 3 before the CAR-T cell infusion. The fludarabine infusion takes about 30 minutes, and the cyclophosphamide infusion takes 30–60 minutes.
A few days after treatment, all study participants will receive an infusion of CAR-T cells. Follow-up visits will last about one year.
Inclusion Criteria
To participate in the study, a person must meet the following requirements:
- The participant has large-cell B-cell lymphoma and has already been treated for this disease at least once.
- The participant is scheduled to receive CAR-T cell therapy.
- The participant is over 18 years of age.
Exclusion Criteria
Individuals who meet any of the following criteria are not eligible to participate in the study:
- Use of an experimental drug during the four weeks prior to chemotherapy.
- CAR-T cell therapy within the 12 months prior to chemotherapy.
- Use of bendamustine in the three months before the T cells are collected for CAR-T cell therapy.
Hospitals
-
HOCH Health Ostschweiz - Kantonsspital St. Gallen
-
Kantonsspital Aarau AG
-
Kantonsspital Graubünden
-
Luzerner Kantonsspital AG